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Background: Atherosclerosis severity-independent alterations in DNA methylation, a reversible and highly
regulated DNA modification, have been detected in aortic atheromas, thus supporting the hypothesis that
epigenetic mechanisms participate in the pathogenesis of atherosclerosis. One yet unaddressed issue is whether
the progression of atherosclerosis is associated with an increase in DNA methylation drift in the vascular tissue.
The purpose of the study was to identify CpG methylation profiles that vary with the progression of atherosclerosis
in the human aorta.
Methods: We interrogated a set of donor-matched atherosclerotic and normal aortic samples ranging from
histological grade III to VII, with a high-density (>450,000 CpG sites) DNA methylation microarray.
Results: We detected a correlation between histological grade and intra-pair differential methylation for 1,985
autosomal CpGs, the vast majority of which drifted towards hypermethylation with lesion progression. The
identified CpG loci map to genes that are regulated by known critical transcription factors involved in atherosclerosis
and participate in inflammatory and immune responses. Functional relevance was corroborated by crossing the DNA
methylation profiles with expression data obtained in the same human aorta sample set, by a transcriptome-wide
analysis of murine atherosclerotic aortas and from available public databases.
Conclusions: Our work identifies for the first time atherosclerosis progression-specific DNA methylation profiles in the
vascular tissue. These findings provide potential novel markers of lesion severity and targets to counteract the
progression of the atheroma.
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DNA methylation is an important epigenetic mechanism
of transcriptional regulation [1,2]. The DNA methylome
undergoes programmed changes during cellular differen-
tiation, but it can be also modified by exogenous stimuli
such as the diet and environmental factors, some of
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article, unless otherwise stated.risk factors [3,4]. Therefore, it has been proposed that
the latter may act by imposing aberrant, proatherogenic
DNA methylation patterns [5,6]. Indeed, differentially
methylated sites mapping to genes participating in
atherogenesis have been identified by candidate gene-
based studies and in a recent epigenome-wide survey of
normal and atherosclerotic human aortas, which showed
a genome-wide increase in DNA methylation in athero-
sclerosis [7-9]. Accordingly, biochemical inhibition of
DNA methyltransferase activity decreases vascular lesion
size in mice [10,11]. Furthermore, epigenome-wide asso-
ciation studies (EWAS) have linked peripheral blood cell
DNA methylation profiles of specific loci to hyperlipid-
emia, hyperglycemia and obesity, thus uncoveringd Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Sample origin and workflow for the presented data.
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osis and metabolic conditions predisposing to athero-
sclerosis [12-14].
By exploiting a high-coverage DNA methylation micro-
array [15] that determines the methylation status of more
than 450,000 CpG sites in the human genome, we previ-
ously identified a set of CpG loci (dm-CpGs) that are differ-
entially methylated between donor-matched atherosclerotic
and normal human aortas [9]. dm-CpG methylation pro-
files are independent of lesion histological grade in the
grade III-VII range, suggesting that they are established
relatively early in the evolution of the atheroma. One ques-
tion left unanswered in our previous study is whether DNA
methylation changes at any CpG loci during the progres-
sion of aortic atherosclerosis. To address that issue, we
searched the original array data [9] for DNA methylation
profiles that are significantly correlated with the histological
grade of the atheroma.
Methods
Human vascular samples
The post mortem donor-matched atherosclerotic and
non-atherosclerotic portions of human aortas (referred
to as “donor-matched sample pairs”) were previously
described [9].
Aortic samples were obtained at the Bellvitge Hospital
and the Clinic Hospital in Barcelona, Spain according to a
protocol approved by the ethics committee of the Bellvitge
Hospital (authorization no. PR311/11) and following
signed consent by the relatives. Post-mortem time was be-
tween 3 and 26 h. Atherosclerotic and normal (A and N,
respectively) portions were macroscopically identified by a
trained Pathology Technician. Approximately 3-cm long
segments of each portion were transferred to RNAlater
(Ambion) and refrigerated. A fragment was obtained from
the middle portion of each segment (either A or N) and the
severity of its histological atherosclerosis was scored on the
AHA scale by a qualified Pathologist. The remaining sam-
ples were transferred to −80°C within 1 day of dissection.
Atherosclerotic lesions and the underlying media were used
in all the procedures described here. The relevant donor
(age, sex) and sample information for the aortic specimens
is shown in Additional file 1: Table S1 in Zaina et al. [9].
A diagram describing the sample origin and workflow
is presented in Figure 1.
DNA methylation analysis
The microarray-based DNA methylation analysis was
conducted with the Infinium HumanMethylation450
BeadChip (450 k array). DNA quality checks, bisulfite
modification, hybridization, data normalization, statis-
tical filtering and Beta value calculation were carried out
as described elsewhere [15,16]. SNP-harboring probes
(11,858) obtained from the list provided by Illumina(support.illumina.com/downloads/infinium_hd_methyla-
tion_snp_list.html) were excluded from the analysis. The
array data for the samples presented here are extracted
from our previously validated and published data set [9],
freely available at the Gene Expression Omnibus (GEO)
database: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token=zfephwswcyoeotw&acc=GSE46401. The methyla-
tion level for each cytosine was expressed as a Beta value
calculated as the fluorescence intensity ratio of the
methylated to unmethylated versions of the probes. Beta
values ranged between 0 (unmethylated) and 1 (methyl-
ated). The annotation relating to CGIs uses the follow-
ing categorization: “shore”, each of the 2 kb-sequences
flanking a CGI; “shelf”, each of the 2 kb-sequences next to
a shore; “open sea”, DNA not included in any of the previ-
ous sequences or in CGIs2. TSS200 orTSS1500 indicate
the region between position −200 bp or −1,500 bp from
the Transcription Start Site (TSS), respectively. Functional
gene annotation was performed with the DAVID database
(http://david.abcc.ncifcrf.gov). Clustering was performed
by Ward’s hierarchical clustering method, using simultan-
eously samples and CpGs.
Whole genome bisulfite sequencing data of one ath-
erosclerotic (grade VII)/normal human aortic tissue
pair were previously published [9]. The complete
DNA methylation sequence at the single nucleotide
resolution is freely available at the GEO database:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=z
fephwswcyoeotw&acc=GSE46401.
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The mouse experimental protocol was approved by the
ethics committee of the Department of Medical Sciences,
University of Guanajuato, León, Mexico. Apolipoprotein
E-null (APOE-null) mice homozygous for the disrupted
Apoe allele [17] and sex- and age-matched WT siblings
were obtained by mating heterozygous mutants that have
been maintained in the C57BL/6 background for >100
generations. Mice were fed a normal chow diet (LabDiet
5001) until sacrifice at the age of 1.6 years. After culling by
decapitation under anesthesia with Isoflurane (Forane,
Baxter), tissues were dissected and kept in RNAlater
(Ambion) at −80°C. Aortas were flushed in situ with PBS
by cardiac puncture after removal of the thoracic and ab-
dominal organs, and carefully cleaned of any fat tissue
under the microscope. Trizol-extracted RNA Integrity
Number (RIN) and concentration was measured using the
Agilent 2100 Bioanalyzer system. After verifying that each
sample presented a RIN number > = 7, Illumina RNA-seq
libraries were prepared using the TruSeq RNA Sample
Preparation Kit, following the vendor instructions and the
resulting cDNA libraries were sequenced using the Illu-
mina Genome Analyzer IIx platform with a Paired End
configuration of 144 cycles (72 bp read length pairs). The
resulting reads were mapped using the BWA aligner (ver-
sion 0.7.5a-r405) with default parameters [18] to a compil-
ation of CDS sequences from the mouse reference
genome (Mus musculus strain C57BL/6 J GRCm38.p2
C57BL/6 J) downloaded from ENSEMBL database using
BioMart (http://www.ensembl.org/biomart). Duplicates
were discarded by using the Picard MarkDuplicate tool
(http://picard.sourceforge.net) and from the filtered align-
ment, the read count for each gene was calculated. The
gene differential expression analysis between the wild type
and mutant mouse aortas was performed using the
NOIseq R package [19] with TMM normalization and a
cutoff line of 0.9 (ranking score) for differential expres-
sion significance, which means that a certain gene is
about 20 times more likely to be differentially expressed
than non-differentially expressed. RNA-seq data are
available in the NCBI BioProject database (Project ac-
cession PRJNA262445).
Statistical analysis
In the case of 450 k arrays, Beta values were converted
to M values by a Logit transformation [20]. Intra-pair
differences in M values were correlated (Spearman’s cor-
relation test) with the histological grade (III-VII range)
converted to numeral values. The correlation test was
used as a first filter to identify CpGs that exhibit a sig-
nificant methylation change with histological grade and
to determine the direction of that change (i.e. progres-
sive hypermethylation or hypomethylation). The signifi-
cance of the identified CpGs was corroborated byANOVA adjusted for age, sex and post mortem time.
The significance threshold in whole 450 k array data
analysis was a Bonferroni-corrected p < 10−7, corre-
sponding to an uncorrected p < 0.05. As for the statis-
tical power, the paired analysis of the same sample (n =
15 pairs) yielded a sizeable number of CpG sites with
significant differential methylation after Bonferroni cor-
rection [9]. Therefore, we assumed that the sample size
would provide the sufficient power for the statistical
analysis presented here. As Beta values are a more intui-
tive representation of methylation profiles, they will be
used to describe the data in the Results and Discussion
sections. Percentages were compared by using the Chi-
square test. The Pearson’s correlation test was used to
compare RNA-seq-derived gene expression level with
the direction of methylation change (i.e. the correlation
r between the delta-M and histological grade). All tests
were performed using the STATISTICA software.
Results
Aberrant DNA methylation profile of atherosclerotic
lesions becomes more frequent with histological grade
We sought DNA methylation profiles that changed with
the progression of atherosclerosis. To this end, we con-
ducted a correlation analysis between the methylation M
value difference within donor-matched atherosclerotic
(A)/normal (N) aortic sample pairs (n = 15) and the re-
spective lesion grade for the >450,000 CpG sites profiled
by the Infinium HumanMethylation450 BeadChip (450 k
array). Aortic sample histological grade ranged from III
to VII. Significantly correlated CpG sites will be referred
to as grade-CpGs. We set the following criteria to assign
a grade-CpG status: 1) absolute difference >0.05 between
the average intra-pair Delta-Betas of the extreme histo-
logical grade subsets - i.e. grade III and grade VII. 2) Sig-
nificant (p < 0.05) Spearman’s correlation rho between
histological grade and intra-pair Delta-M, and no signifi-
cant correlation with donor’s age, sex and post-mortem
time. The significant of the correlation test result was
further corroborated by submitting the identified CpG
set to ANOVA with donor’s age, sex and post-mortem
time as covariates (significance threshold p < 0.05). 3)
No significant difference between M values of grade VII
and grade III N samples, to exclude possible confound-
ing factors that might over- or underestimate the effect
of histological grade.
We identified 1,985 autosomal CpG sites (correspond-
ing to 1,206 genes) that matched the grade-CpG criteria
(Additional file 1: Table S1). Spearman’s correlation r-
values ranged from 0.863 (p = 3.4×10−5) to −0.558 (p =
0.031), thus no grade-CpG displayed a significance level
below the Bonferroni-corrected p-value. Yet, clustering
analysis of the 1,985 grade-CpGs showed a clear group-
ing by low (III-IV) and high (V-VII) histological grade,
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grade samples (Figure 2A). Accordingly, the vast majority
of the grade-CpG methylation profiles (1,631 or 82.2%)
correlated positively with atherosclerosis grade, suggesting
a gradient change of DNA methylation with disease pro-
gression, predominantly towards hypermethylation in
advanced lesions (Figure 2B). On average, grade-CpGs dis-
played weak differential DNA methylation (average abso-
lute grade III versus grade VII A sample Delta-Beta =
0.069; range: 0.050 to 0.522). Notably, 111 genes contained
both grade-CpGs and the previously described histo-
logical grade-independent dm-CpGs [9]. Thus, grade-
CpGs reinforced the DNA methylation drift represented
by dm-CpG. As examples, two relevant genes are shown,Figure 2 Features of grade-CpGs. A, Supervised clustering analysis of the
are shown for each sample. Note the tendency for hypermethylation in the a
improve readability, as changes in DNA methylation were overall weak (see in
of grade-CpGs with positive (i.e. hypermethylation with lesion grade) and
C, Intra-pair Delta-Beta and position of grade-CpGs (black diamonds) and
PRDM16 gene-body. Notice that grade-CpGs reinforce the dm-CpG profile
observed distribution; open bars, distribution of 450 k array probes.one involved in vascular smooth muscle cell (VSMC)
proliferation (platelet-derived growth factor alpha
polypeptide, PDGFA) [21] and the other participating in
the induction of repressive chromatin, in adipose tissue
homeostasis and identified as part of the gene expression
signature of stable atherosclerotic plaques (PR domain
containing 16, PRDM16) [22-24] (Figure 2C).
As for genomic distribution, grade-CpGs mapped pref-
erentially to gene bodies and were underrepresented in
promoters (Chi-square test, p = 0.029, compared with the
probe distribution on the 450 k array), whereas their dis-
tribution relative to CGIs was only marginally different
from expected (p = 0.059) (Figure 2D). When grade-CpGs
were grouped according to the direction of methylation1,985 grade-CpGs. Donor’s number and corresponding lesion grade
dvanced lesion group. Heatmap color and contrast were enhanced to
tensity distribution above upper right corner of heatmap). B, Proportion
negative correlation between lesion grade and intra-pair Delta-Beta.
the previously described dm-CpGs (open circles) in the PDGFA and
s. D, Grade-CpG mapping relative to gene compartments. Solid bars,
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the genomic distribution were observed. First, CGIs were
significantly underrepresented within the hypomethylated
grade-CpG set in comparison with the hypermethylated
counterpart (6.7% and 21.5%, respectively, Chi-square p =
2.39 × 10−5), whereas only a marginal difference in distri-
bution was observed relative to gene compartments (p =
0.07). Second, CpGs undergoing hypomethylation were
initially highly methylated - i.e. in the N (baseline) sam-
ple, while the hypermethylated counterparts were
evenly distributed across the 0–1 Beta range in the N
sample (average Beta 0.63 ± 0.20 and 0.48 ± 0.26 for the
hypomethylated and hypermethylated grade-CpGs, re-
spectively; t-test p = 5.35 × 10−31) (Additional file 2:
Figure S1A,B). Accordingly, when grade-CpGs of either
set were further fractioned by N sample methylation
level (high: Beta > 0.75; intermediate: 0.75 ≥ Beta ≥ 0.25;
low: Beta < 0.25), a significant underrepresentation of
the low methylation fraction within hypomethylated
grade-CpGs was observed (7.6% and 26.3% in hypome-
tylated and hypermethylated grade-CpGs, respectively;
Chi-square p = 2.3 × 10−5) (Additional file 2: Figure
S1C). Thus, the histological grade-related hypomethyla-
tion and hypermethylation differed, as the former tar-
geted highly methylated CpGs preferentially outside
CGIs, in comparison with the latter.
Functionally, grade-CpG-harboring genes were signifi-
cantly enriched in biological processes involving immune
and inflammatory response genes (Fc-gamma receptor-
mediated phagocytosis, peroxisome proliferator-activated
receptor (PPAR) signaling, T-cell receptor signaling, im-
mune cell-specific expression; Fisher’s exact test, p < 0.05)
(Table 1). Noticeably, genes regulated by the transcrip-
tional factors ZEB1 (AREB6) and PPAR-gamma, involved
in the cellular response to oxidized lipoproteins and
macrophage activation [25,26], respectively, were signifi-
cantly enriched (949 and 924 genes, p = 4.2 × 10−10 and
p = 2.4 × 10−10) (Table 1). Eighteen grade-CpGs mapped
to 9 genes previously identified as differentially methylatedTable 1 Synopsis of selected relevant biological processes en
Category Genes
Fc-gamma receptor phagocytosis DNM3, LYN, PIK3CD, WASF2, PIP5K1B,
Type 2 diabetes mellitus PRKCZ, IRS2, PIK3CD, CACNA1E, MAPK
T-cell receptor signaling HLA-DRB1, PRKAR1B, CREBBP, GNAS, C
Gene regulation by PPAR-alpha LPL, PDGFA, PRKAR1B, EHHADH, CREB
Interaction with ZEB1 949 genes*
Interaction with PPAR-gamma 924 genes*
Tissue specificity:
Leukocyte CAST, KLF6, TRAF2, TNXB, HLA-DRB1, N
Lymphocyte HLA-DRB1, HLA-C, HLA-DPB1
*List available upon request. PPAR, Peroxisome proliferator-activated receptor; ZEB1in atherosclerosis by candidate gene-based or epigenomics
studies (Table 2). Furthermore, 24 grade-CpGs were lo-
cated within 250 kb from 16 cardiovascular disease-
associated single nucleotide polymorphisms (SNPs) [27],
suggesting an interplay between the risk genotype and dif-
ferential DNA methylation as methylation quantitative
trait loci (Additional file 3: Table S2) [28]. When grouped
according to the direction of methylation change with
histological grade, hypermethylated grade-CpG-harboring
genes were enriched for the same functional categories as
the bulk of grade-CpGs, while no significant enrichment
was observed for the hypomethylated counterpart (not
shown). Based on our data, we cannot conclude whether
the latter result reflects an underlying biological property
or is due to a sample size effect.
We performed a technical validation of 450 k data by
comparing the promoter grade-CpG methylation profiles
with our previous whole genome bisulfite sequencing
(WGBS) data for one of the donor-paired aortic samples
presented here (sample 93, displaying a grade VII lesion)
[9]. Eighteen promoter grade-CpGs mapped to promoter
differentially methylated regions (DMRs) identified by
WGBS. The correlation between the average intra-pair
Delta-Beta of grade VII aortic samples (n = 9) and the
intra-pair difference in methylation for the single WGBS
aortic sample was significant (r = 0.540, p = 0.021, n = 18),
thus ruling out technique-related confounding factors. As
for biological validation, the same 450 k array data from
which the grade-CpG profiles were obtained, were previ-
ously validated in 15 discovery and 24 validation paired
aortic samples [9], including the grade-CpG-harboring
genes PDGFA and C9orf3/MIR23b.
A grade-CpG subset is differentially expressed in human
atheromas and in a heterologous model of advanced
atherosclerosis
To further corroborate the pathobiological relevance of
grade-CpGs, we crossed their methylation profiles with
expression data obtained experimentally or from publicriched for genes mapping to grade-CpGs (p < 0.05)
PIP5K1A, PRKCE, AMPH, MYO10, RAC1, SCIN, PPAP2A, DNM1
10, MAFA, CACNA1C, PRKCE, CACNA1A, CACNA1B
SK
BP, HSPA1A, NCOR2
TF3, MYO7A, RHD, HLA-C, TLR5, MEN1, JUP, CD9, IKBKE, UMPS, ADAP2, NT5E
, Zinc finger E-box binding homeobox 1.
Table 2 Grade-CpG-containing genes identified in
previous studies as differentially methylated in
atherosclerosis or related metabolic conditions
Gene CpG ID Map Correlation rho
between Delta-M
and lesion grade
C1QL4 [29] cg12760869 Gene-body 0.56
CTNNA3 [29] cg04030146 Gene-body 0.54
cg07002403 Gene-body −0.53
DCC [12] cg24270629 Gene-body 0.52*
ESR1 [30] cg15626350 Gene-body 0.54
HSPA1A [31] cg24888257 First exon 0.53
IMMT [29] cg10973622 Promoter 0.55










SLC16A3 [33] cg23664708 3′ UTR 0.52
*Opposite change in DNA methylation in our study and the cited original work.
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previously showed that differential methylation coin-
cided with significant changes in expression in aortic
samples [9]. Furthermore, 105 grade-CpG-harboring
genes overlapped with a human atherosclerotic plaque-
specific genes expression signature [24], and 87 over-
lapped with the list of atherosclerosis-related genes in
the HuGENet™ database. The full list of the overlapping
genes is shown in Additional file 4: Table S3. Overlapping
genes are involved in relevant functions such as lipid
homeostasis (ALOX12, CETP, LPL, LRP1, LRP5, PLA2G2A),
chemokine signaling (CCR5), VSMC proliferation (PDGFA),
atheroprotection (ESR1), local inflammatory response
(VCAM1, C3, ITGB2) and T-cell receptor signaling (genes
listed in Table 1).
Next, we asked whether any grade-CpG-harboring gene
was differentially expressed in a mouse model of advanced
atherosclerosis. We reasoned that a strong correlation be-
tween human aortic DNA methylation profiles and gene
expression in a heterologous model will identify grade-
CpGs with potential pathobiological relevance and suit-
ability for comparative mouse model studies. To this end,
we performed a RNA-seq-based gene expression analysis
in aortic atherosclerotic lesions of one 1.6 years old male
APOE-null mouse, a model of hyperlipidemia-induced
atherosclerosis [17] and one congenic, sex- and age-matched WT sibling. As expected in a mutant mouse of
advanced age, the thoracic aorta showed extensive athero-
mas (Additional file 2: Figure S2). The relevant descriptive
statistics for the RNA-seq analysis of WT and mutant aor-
tic samples is shown in Additional file 5: Table S4. After
comparing the samples using the NOIseq R package,
among the genes showing a >2-fold expression difference
between mutant and control mice, 53 up-regulated and 40
down-regulated genes in the APOE-null mouse harbored
grade-CpGs. A total of 99 grade-CpGs mapped to those
93 differentially expressed mouse genes (mgrade-CpGs).
The mouse genes and corresponding grade-CpGs are
listed in Additional file 6: Table S5. The 23 promoter
mgrade-CpGs showed a significant inverse correlation
between the histological grade-associated methylation
change (i.e. the Spearman’s correlation rho between the
methylation status and histological grade) in human aortas
and the differential expression of the corresponding mouse
genes - i.e. APOE-null relative to WT (Pearson’s r = −0.71,
p = 1.5×10−4). Thus, the aberrant methylation of promoter
grade-CpGs during atherosclerosis progression is associated
with an expected expression change of the corresponding
gene in a heterologous advanced lesion. A significant in-
verse correlation for open sea grade-CpG was also observed
(r = −0.384, p = 0.009, n = 46), reflecting the abundance of
promoter and 5′ gene portions (5′UTR, first exon) map-
ping to open sea in the mgrade-CpG set (21 out of 46, or
45.6%). The methylation status of gene-body mgrade-CpGs
did not show any significant correlation with expression in
accordance with the published evidence that intragenic
methylation may enhance or repress transcription in a
context-specific manner [34,35] nor did CpG island-,
shore- or shelf-mapping mgrade-CpGs (data not shown).
As for gene function, 29 of the mgrade-CpG-harboring
up-regulated genes in the APOE-null aorta were targets of
the master regulator of inflammation nuclear factor kappa
B (NFKB) [36], (p = 1.8 × 10−4). Interestingly, pathway
analysis (BioCarta) revealed enrichment in local inflamma-
tory response and transcription regulation by the arginine
methyltransferase CARM1 genes (PRKAR1B, RARA) (p =
0.006 and p = 0.05, respectively). These results are consist-
ent with the participation of CARM1 in NFKB transcrip-
tional activation [37]. Of the down-regulated genes, 32
were regulated by myocyte enhancer factor 2A (MEF2A),
a transcription factor implicated in coronary artery disease
(p = 3.5 × 10−7) [38]. Notably, the observation that loss of
MEF2A leads to VSMC dedifferentiation is consistent with
the enrichment of its targets in the down-regulated gene
set [39].
Discussion
We detected a significant correlation between intra-
aortic pair DNA methylation Delta-Beta and lesion
histological grade for 1,985 autosomal CpGs (grade-
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testing-corrected significance level, the results are of po-
tential interest due the convergence of multiple inde-
pendent supporting evidence. First, we observed a
progressive increase in methylation of macrophage func-
tion and immunity genes with atherosclerosis progres-
sion, reflecting the well-characterized migration of
immune and inflammatory cells into the vascular wall
and lesion mass during the natural history of athero-
sclerosis [40]. Second, the hypermethylation of the ma-
jority of grade-CpGs with lesion severity represents an
exacerbation of the hypermethylated profiles of previ-
ously described atherosclerosis-specific dm-CpGs [9].
dm-Cpgs are lesion progression-independent profiles
and therefore represent an epigenetic drift of the vascu-
lar genome that is already present in low-grade lesions
and is amplified by grade-CpGs during lesion progres-
sion. Although overlapping in selected loci, the bulk of
dm-CpGs and grade-CpGs map to functionally distinct
genes, i.e. to SMC-related and immune/inflammatory
genes, respectively, pointing to the specific regulation of
different pathways in early and progressing atheroscler-
osis [9]. Noticeably, the hypermethylation of the majority
of grade-CpGs in high-grade lesions matches the obser-
vation that high expression of the DNA methyltransfer-
ase DNMT1 is a signature of inflamed, advanced human
plaques [24]. Interestingly, histological grade-related
hypermethylation indiscriminately targeted low, inter-
mediate and high methylation CpGs, whereas hypome-
thylation showed a preference for initially (N sample
baseline) highly methylated CpGs in CG-poor regions.
Further studies will be necessary to fully elucidate the
mechanisms and the biological significance of this obser-
vation. Third, the genomic distribution of grade-CpGs
generally reflects the one of dm-CpGs, suggesting a
common instructive mechanism of DNA methylation
drift, particularly the preference for gene-body hyperme-
thylation, despite the functional differences mentioned
above. Fourth, several grade-CpGs map to previously
identified differentially methylated genes in atheroscler-
osis. In particular, both a previous epigenomics study
carried out in peripheral blood samples [29] and our
work in the aorta [9], identify differential methylation in
the C1QL4, CTNNA3 and IMMT genes. These loci
undergo an epigenetic drift towards hypermethylation in
independent cardiovascular sample sets representing dif-
ferent tissues and are therefore potential important func-
tional markers. Lastly, we crossed the methylation profiles
with available public human databases and transcriptome-
wide expression data for a mouse aortic lesion. Although
the expression data lack replicates, we used an analysis
package (NOIseq) that was developed for differential ex-
pression analysis conditions with no replicates as a non-
parametric algorithm that evaluates the significance ofgene expression changes by comparison against data noise
simulation [19]. Hence, the strong inverse association be-
tween the methylation status of human promoter grade-
CpGs and the expression levels in that heterologous
model strongly suggest a general pathobiological relevance
for grade-CpGs.
Conclusion
We provide for the first time a list of CpG loci in the vas-
cular lesion genome that undergo a DNA methylation
drift with the progression of the lesion. The identified
grade-CpGs represent promising markers of atheroma
progression or targets to counteract the progressive DNA
hypermethylation associated with the natural history of
atherosclerosis.
Availability of supporting data
The DNA methylation array data have been deposited
in the Gene Expression Omnibus (GEO) database:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=
zfephwswcyoeotw&acc=GSE46401.
The RNA-seq data have been deposited in the NCBI Bio-
Project database (www.ncbi.nlm.nih.gov/bioproject) with
project accession: PRJNA262445.
Additional files
Additional file 1: Table S1. List of autosomal grade-CpGs.
Additional file 2: Figure S1. Differential distribution of grade-CpGs that
undergo hypermethylation or hypomethylation with histological grade,
among N sample Beta classes. A,B: N sample Beta of hypermethylated
and hypomethylated CpGs (rho>0 and rho<0, respectively). CpGs are
ordered for decreasing methylation/grade Spearman’s rho (left to right).
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